

Oasmia presents Q3 report through audiocast on March 27

Oasmia will hold an audiocast and telephone conference on Friday 27 March at 10:00 (CET) to present the company's Q3 report for the financial year 2019/2020.

The presentation of the Q3 report will be in English.

Presenters will be Francois Martelet, CEO, and Michael af Winklerfelt, CFO.

The audiocast is viewed via the link

<https://tv.streamfabriken.com/oasmia-pharmaceutical-q3-2019-2020>

It will be possible to ask texted questions directly via the Audiocast solution.

Telephone number for the conference call is

SE: +46850558353

UK: +443333009262

US: +18332498407

For more information:

Urban Ekelund, IR Manager Oasmia

Phone: +46 18-50 54 40

E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR17. Oasmia has been successful in driving its first product candidate, Apealea (paclitaxel micellar), through clinical development, and has applied for and achieved market approval in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients.

Attachments

[Oasmia presents Q3 report through audiocast on March 27](#)